Dr. Amy Proal in collaboration with the Cohen Center for Recovery from Complex Chronic Illness this week: “A big goal of ours is that [Long COVID] diagnostics are available to be ordered in insurance care for the most number of patients…

“What we’re finding across the genome are specific variants that are very much enriched, and have highly likely loss-of-function in these patients with [severe] Long COVID,” said Dr. Petter Brodin on his team’s PolyBio-supported genome study of Long COVID patients.

Written summaries of PolyBio’s Spring symposium presentations are available now! Check out shortened, simplified summaries, or full technical explanations of your favourite research projects. 2026-spring-symposium-polybio.netlify.app #Longcovidresearch #mecfsresearch #chroniclymedisease

Breaking: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Low-Dose Rapamycin Clinical Trial with a New Open-Label Phase 1/

Breaking: PolyBio-Supported Study Identifies Association between HHV-6 Reactivation & Long COVID Symptom Severity The work adds to growing evidence that chronic viral reactivation may contribute to the biological mechanisms underlying Long COVID. Read more: polybio.org/polybio-supp...

PolyBio-Supported Study Identifies Association Between HHV-6 Reactivation and Long COVID Severity - PolyBio Research Foundation

A collaborative study between the laboratory of Akiko Iwasaki at Yale University and the Icahn School of Medicine at Mount Sinai has identified a potential link between reactivation of the herpesvirus...

polybio.org

Putrino Lab@putrinolab.bsky.social · 2mo ago

We have known for a while that #LongCOVID pathobiology for many involves reactivation of various herpesviruses. As we continue to validate this it is great to see this work coming out in collaboration with @VirusesImmunity’s incredible team. Here we www.medrxiv.org/content/10.6... 1/

Excited for PolyBio’s upcoming Spring symposium on Friday, May 22 from 11 AM to 5 PM ET? Here’s the full program of presenters you’ll hear from!

Catch Dr. Michael Peluso, part of the PolyBio-supported Long COVID tissue bank & LIINC collaborative, in Men’s Health this week! Read the full article here: www.menshealth.com/health/a7113... #longcovidtreatment #longcovidresearch #menshealth

Park-Pagliuca Fund Donates $10 Million to PolyBio Long COVID Cure Initiative The funding will fast-track Long COVID diagnostics and treatments 🧵 www.prnewswire.com/news-release...

Save the date! PolyBio’s Spring symposium will take place on Friday, May 22 11-5 PM ET. It will feature project updates on Long COVID, ME/CFS, Alzheimer’s & chronic tick-borne disease research that is advancing how we diagnose & treat IACIs. Sign up now: us02web.zoom.us/webinar/regi...

BREAKING: VIPER Diagnostics Program Launches as First Phase of PolyBio Long COVID Cure Initiative Program will validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID, providing a path to targeted treatments.

PolyBio Research Foundation is keeping you in-the-know with our newly launched newsletter! Sign up for our mailing list to get direct project updates to your inbox & meet the team that drives our research forward. polybio.org/newsletter/

Interested in low-dose Rapamycin for Long Covid? The Cohen Center for Recovery from Complex Chronic Illness is actively recruiting for a RCT of the mTOR inhibitor Sirolimus (Rapamycin). The trial aims to evaluate if changes to the immune response as a result of the drug improve Long Covid symptoms.

1/ Long Covid, ME/CFS and Post-Treatment Lyme patients living in NYC: Mount Sinai’s CoRE clinic is actively recruiting for a clinical trial of Lumbrokinase. This enzyme breaks down fibrin, a coagulation factor linked to chronic symptoms,

PolyBio scientific advisory board member Dr. William Eimer led the recent discovery of beta-amyloid & tau proteins’ antimicrobial activity targeting Herpes Simplex Virus 1 in the brain. (1/2)

PolyBio CEO Dr. Amy Proal & PolyBio-supported researchers Timothy Henrich MD & Steven Deeks MD recently presented data on Long Covid tissue findings at the inaugural USA-Saudi Biotech Alliance summit. polybio.org/polybio-scie...

Want first access to antiviral therapies for Long Covid? We’re looking for participants for a clinical trial of Truvada & Maraviroc. The trial is using cutting-edge biological markers including deep immune profiling & EndoPAT to determine efficacy of these medications in LC.

BREAKING: PolyBio Core Team Collaborating with Invivyd for Trial of the mAb VYD2311, Launching mid-2026 This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.

“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.

Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.

To wrap-up our countdown to 2026, we’re highlighting PolyBio’s key contribution to the UCSF LIINC Anktiva trial for Long Covid. The funding will allow advanced testing of patient samples to track changes in SARS-CoV-2 persistence over time.

No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments. #polybio2026countdown

PolyBio’s influential 2025 moments no.10: our contribution to developing advanced diagnostics for Babesiosis. The new methods will allow the research team to assess the prevalence of different Babesia species in over 1400 patients with a spectrum of cardiac, rheumatological & neurological disorders.

No.9 on PolyBio’s End-of-Year countdown: the Banbury meeting on accessible diagnostics of pathogen tissue persistence. The meeting brought together leading scientists to accelerate progress toward reliable diagnostics for infection-associated chronic diseases, including Long COVID.

No.8 on our list of influential PolyBio moments in 2025: the expansion of LIINC to study pre-2019 ME/CFS. The study will investigate key biological drivers of ME/CFS, including persistent gut enterovirus infections and T-cell over-activation in the CNS. #polybio2026countdown

2025 was the year that PolyBio began launching several clinical trials—importantly, the RCT of repurposed HIV antivirals Truvada & Maraviroc for Long Covid at the CoRE clinic. #polybio2026countdown

One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging. “As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.” #polybio2026countdown

A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials. www.latimes.com/opinion/stor... #polybio #polybio2026countdown

Looking back at some of PolyBio’s most influential moments of 2025–we can’t forget about this collaborative effort between Dr. Iwasaki’s Yale team & Dr. Bragée’s ME/CFS clinic in Sweden. The PolyBio-supported study used cerebrospinal fluid to identify 2 distinct ME/CFS subtypes.

Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown

Breaking: PolyBio joins HHS Lyme Disease roundtable meeting, as new clinical trial advances treatment for Chronic Babesiosis This week, PolyBio President Dr. Amy Proal attended a U.S. Department of Health and Human Services–convened Lyme Disease roundtable meeting. 🧵